Rna Diagnostics Inc.

Rna Diagnostics, a clinical stage molecular diagnostics company, is commercializing a practice changing cancer diagnostic platform technology: VERIDAPT DX TM

  • Stage Full Product Ready
  • Industry Medical Devices and Equipment
  • Location Toronto, ON, Canada
  • Currency CAD
  • Founded March 2010
  • Employees 10
  • Incorporation Type Other
  • Website http://rnadiagnostics.com

Company Summary

The VERIDAPT DX Lab Developed Test service meets a large unmet need in cancer treatment; how to assess if patients are responding or are resistant to a given drug regimen. VERIDAPT DX optimizes cancer therapy based on measurement of a patient's biological response to drug treatment in real time. Clinical evidence in > 1000 patients. No FDA approval required. Near term value inflection with readout of large-scale prospective clinical trial.

Team

  • John Jordan, MBA, CMA, CPA/ABV (US)
    Chief Financial Officer

    Financial executive with 15 years experience taking early stage technology companies from start-up through to successful exit

  • Amadeo, PhD Parissenti
    Chief Scientific Officer

    Professor of biochemistry at Laurentian University. Over 20 years experience studying tumour resistance to chemotherapy.

  • John Connolly, MBA
    President and Chief Executive Officer

    20 year entrepreneur in medical technology business development , former patrner at MDS Capital Corp, Health Science venture capital investor

  • John Connolly

Advisors

  • Stikeman Elliott
    Lawyer
    Unconfirmed

Previous Investors

  • Niagara Angels, Ontario Centres of Excellence
    Unconfirmed
  • York Angel Investors
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free